Metadeq

Elevate connects innovative medical knowledge with didactics.

Metadeq, Inc. is committed to delivering diagnostics that help physicians identify, diagnose, stage and monitor MASLD and MASH patients with a simple and accurate blood test.

Metadeq’s lead product is HeparDx™, a blood test based on two biomarkers to detect MASH activity and liver fibrosis. This novel blood test is designed to improve accuracy of current non-invasive tests and can be used to: detect MASH in clinical practices, improve clinical trial screen failure rates, and monitor patient response to therapy.

Clinical data from a prospective study in 250 patients undergoing liver biopsies has been peer-reviewed and published in Gut, a leading medical journal.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, Efpia, EuropaBio, MedTech Europe, Vaccines Europe and Mercodia Aktiebolag, Metadeq Limited and Julius Clinical Research BV.

Funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.